Macrocyclic ULK1/2 inhibitors for cancer treatment
Summary
The USPTO has granted patent US12594277B2 to the Sal k Institute for Biological Studies covering macrocyclic ULK1/2 inhibitors and their therapeutic applications. The patent includes 8 claims directed to compounds and methods for treating cancer using ULK-mediated diseases. The patent expires April 2026 with a February 2021 filing date.
What changed
The USPTO issued patent US12594277B2 to the Sal k Institute for Biological Studies, covering macrocyclic ULK1/2 kinase inhibitors and pharmaceutical compositions comprising said compounds for treating cancer and other ULK-mediated diseases. The patent names Nicholas D. P. Cosford, Nicole A. Bakar, Reuben J. Shaw, Allison S. Limpert, and Sonja N. Brun as inventors and grants exclusivity through April 2026.\n\nPatent holders should monitor for potential inter partes review challenges and consider filing continuation applications. Competitors developing autophagy-targeting cancer therapeutics should assess freedom-to-operate to avoid infringement liability.
What to do next
- Monitor for post-grant proceedings such as inter partes review
- Review freedom-to-operate implications for competitive drug development programs
- Track patent family developments for related international applications
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Macrocyclic ULK1/2 inhibitors
Grant US12594277B2 Kind: B2 Apr 07, 2026
Assignee
SALK INSTITUTE FOR BIOLOGICAL STUDIES
Inventors
Nicholas D. P. Cosford, Nicole A. Bakas, Reuben J. Shaw, Allison S. Limpert, Sonja N. Brun
Abstract
The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ULK mediated diseases, including cancer.
CPC Classifications
A61K 31/529 A61K 31/282 A61K 45/06 C07D 498/08 A61P 35/00
Filing Date
2021-02-12
Application No.
17799634
Claims
8
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.